SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT
The present disclosure relates to the pharmaceutical field. More specifically, it relates to methods for treating a tumor in a human subject in need thereof, said method comprising administering a therapeutically efficient amount of an anti-BTN3A antibody which induces the activation of Vγ9Vδ2 T cel...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
24.07.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates to the pharmaceutical field. More specifically, it relates to methods for treating a tumor in a human subject in need thereof, said method comprising administering a therapeutically efficient amount of an anti-BTN3A antibody which induces the activation of Vγ9Vδ2 T cells, in combination with a therapeutically efficient amount of an anti-PD1/PDL1 treatment, wherein said subject is having relapsed or refractory tumors to anti-PD1/PDL1 treatment. |
---|---|
Bibliography: | Application Number: EP20220801343 |